Fortress Biotech Statistics
Share Statistics
Fortress Biotech has 8.13M
shares outstanding. The number of shares has increased by -87.36%
in one year.
| Shares Outstanding | 8.13M |
| Shares Change (YoY) | -87.36% |
| Shares Change (QoQ) | 223.63% |
| Owned by Institutions (%) | 0.01% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 574 |
| FTD / Avg. Volume | 4.47% |
Short Selling Information
The latest short interest is 474, so 0% of the outstanding
shares have been sold short.
| Short Interest | 474 |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.92 and the forward
PE ratio is null.
Fortress Biotech's PEG ratio is
0.01.
| PE Ratio | -0.92 |
| Forward PE | n/a |
| PS Ratio | 0.73 |
| Forward PS | 0.4 |
| PB Ratio | 1.86 |
| P/FCF Ratio | -0.44 |
| PEG Ratio | 0.01 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Fortress Biotech.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.27,
with a Debt / Equity ratio of 3.34.
| Current Ratio | 1.27 |
| Quick Ratio | 1.06 |
| Debt / Equity | 3.34 |
| Debt / EBITDA | -0.73 |
| Debt / FCF | -0.8 |
| Interest Coverage | -9.53 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $571,039.6 |
| Profits Per Employee | $-455,415.84 |
| Employee Count | 101 |
| Asset Turnover | 0.4 |
| Inventory Turnover | 1.45 |
Taxes
| Income Tax | 312K |
| Effective Tax Rate | -0.26% |
Stock Price Statistics
The stock price has increased by -60.26% in the
last 52 weeks. The beta is 1.86, so Fortress Biotech's
price volatility has been higher than the market average.
| Beta | 1.86 |
| 52-Week Price Change | -60.26% |
| 50-Day Moving Average | 6.1 |
| 200-Day Moving Average | 6.25 |
| Relative Strength Index (RSI) | 52.43 |
| Average Volume (20 Days) | 12,840 |
Income Statement
In the last 12 months, Fortress Biotech had revenue of 57.67M
and earned -46M
in profits. Earnings per share was -2.21.
| Revenue | 57.67M |
| Gross Profit | 36.8M |
| Operating Income | -110.38M |
| Net Income | -46M |
| EBITDA | -104.49M |
| EBIT | -108.95M |
| Earnings Per Share (EPS) | -2.21 |
Full Income StatementBalance Sheet
The company has 57.26M in cash and 75.96M in
debt, giving a net cash position of -18.7M.
| Cash & Cash Equivalents | 57.26M |
| Total Debt | 75.96M |
| Net Cash | -18.7M |
| Retained Earnings | -740.87M |
| Total Assets | 144.22M |
| Working Capital | 18.97M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -80.19M
and capital expenditures -15M, giving a free cash flow of -95.19M.
| Operating Cash Flow | -80.19M |
| Capital Expenditures | -15M |
| Free Cash Flow | -95.19M |
| FCF Per Share | -4.58 |
Full Cash Flow StatementMargins
Gross margin is 63.8%, with operating and profit margins of -191.38% and -79.75%.
| Gross Margin | 63.8% |
| Operating Margin | -191.38% |
| Pretax Margin | -209% |
| Profit Margin | -79.75% |
| EBITDA Margin | -181.17% |
| EBIT Margin | -191.38% |
| FCF Margin | -165.05% |
